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30% decrease in end-stage animals (relative to control). Increased
puncta formation relative to the control average is consistent with
the notion that OPTN expression is upregulated for its ability to
bind cargo.
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Parkinson’s disease (PD) is a neurodegenerative disease
characterized by a resting tremor and slowed movement. These
motor deﬁcits result from cell death in a brain region called the
substantia nigra (SN). Additionally, insoluble clusters of toxic
proteins, termed Lewy Bodies (LB), develop in the brain. Lewy
Body accumulation is reported to increase in scope and severity
as PD progresses and, notably, does not affect the SN until
halfway through disease progression. Therefore, according to the
hypothesis that LB overload ultimately contributes to cell death,
clinical intervention of PD does not occur until cell death in the SN
is imminent.
Autophagy is the cellular process responsible for degrading dysfunctional proteins, which is compromised in PD. Since the failure
of this critical pathway precedes LB development, elucidating the
mechanisms by which autophagy is impaired could allow for earlier attempts targeted at attenuating LB proliferation.
Optineurin (OPTN, green) is a protein critical for autophagy, where
it acts as a cargo adapter by linking substrates for degradation to
the site of autophagic breakdown. Despite mutations in the OPTN
gene being linked to glaucoma and ALS, the protein has received
minimal attention. Given the overlap between disease pathology
and the cellular role of OPTN, I sought to examine OPTN in vivo
(in a living organism).
Rotenone is a naturally occurring pesticide that has been extensively characterized for its ability to recapitulate PD pathology;
in our study, rats received injections for 24 hours, 5 days, or until
the onset of behavioral deﬁcits (typically approximately 7 days
later, which was associated with overt neurodegeneration). We
then performed quantitative immunoﬂuorescence on rat tissues in
order to evaluate changes to OPTN’s distributional conformation
within cells. Additionally, we quantiﬁed OPTN colocalization with
a marker for autophagic vacuoles (LC3, red).

Interestingly, and despite an OPTN conformation that favored
cargo transport, colocalization with autophagic vessels was
signiﬁcantly diminished relative to control average. We observed a
32% decrease at 24 hours and a 37% decrease at 5 days. Although
there are many possible explanations for decreased colocalization,
one likelihood is that OPTN and LC3 migrate to different cargo.
In summary, we have provided the ﬁrst evidence that OPTN is
enriched in clinically relevant PD regions and that distribution
is altered in preclinical environmental PD models. Signiﬁcant
impairment to OPTN–LC3 colocalization also may be indicative of
the impaired autophagy observed in PD. Ultimately, understanding
how PD deﬁciencies manifest themselves in ways beyond motor
dysfunction could allow clinicians to recognize more quickly cases
in order to incorporate appropriate intervention strategies prior to
neurodegeneration.
Research advisor Jason Cannon writes: “Aberrant autophagy
has been linked to the pathogenesis of PD. Yet, where in the brain
and at which disease stages that autophagy disruptions occur
is unknown. Joey’s work has begun to make some important
advances in these areas. In animal models of PD, Joey has helped
to show that key proteins involved in autophagy are altered in
expression and cellular localization prior to cell death, and also
that brain regions involved in both motor and nonmotor symptoms
of PD are affected. His data has implications in understanding the
pathogenesis of Parkinson’s disease and also, potentially, in the
identiﬁcation of new therapeutic pathways.”

Immediately following rotenone administration, we saw signiﬁcant
alterations to OPTN distribution in cells. This change favored
the formation of bright circular dots, termed puncta, by 24%
relative to control animals. In subsequent stages, the percent of
OPTN existing as puncta fell to a 1% increase at 5 days and a

A-D) Representative images
of OPTN (green) and LC3 (red)
expression in control, 24 hour-,
5 day-, and end-stage animals,
respectively; significant increases
to the fraction of cellular OPTN
in punctate conformation and in
cellular LC3 expression are observed at 24 hours; n = 120–170
cells analyzed/group; significance is p < 0.05 for all groups.
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